The Journal of Allergy and Clinical Immunology
Volume 122, Issue 2 , Pages 238-246, August 2008

Exercise and other indirect challenges to demonstrate asthma or exercise-induced bronchoconstriction in athletes

  • Kenneth W. Rundell, PhD

      Affiliations

    • Corresponding Author InformationReprint requests: Kenneth W. Rundell, PhD, Director or Respiratory Research and the Human Physiology Laboratory, Keith J. O'Neill Center for Healthy Families, Marywood University, Scranton, PA 18509.
  • ,
  • Joshua B. Slee, MS

Human Physiology Laboratory, Keith J. O'Neill Center for Healthy Families, Marywood University, Scranton, Pa

Received 10 April 2008; received in revised form 30 May 2008; accepted 2 June 2008.

The prevalence of exercise-induced bronchoconstriction is reported to be high among recreational and elite athletes, yet diagnosis is often symptom-based. Indirect challenges such as the laboratory exercise challenge provide objective criteria for proper diagnosis and treatment. However, a standardized protocol using appropriate exercise intensity, duration, and dry air inhalation is often not implemented, and thus a false-negative test may result. This article reviews and describes the symptom-based diagnosis, the exercise challenge, and other indirect challenges such as eucapnic voluntary hyperpnea, hypertonic saline inhalation, and inhaled powdered mannitol as methods to diagnose and evaluate exercise-induced bronchoconstriction. Advantages and disadvantages of each diagnostic procedure are presented.

Key words: Athlete, bronchoconstriction, diagnosis, EVH, exercise-induced asthma, hypertonic saline, mannitol

Abbreviations used: ATS, American Thoracic Society, EIB, Exercise-induced bronchoconstriction, EVH, Eucapnic voluntary hyperpnea, FVC, Forced vital capacity, HRpeak, Peak heart rate, ICS, Inhaled corticosteroid, IOC, International Olympic Committee, MVV, Maximal voluntary ventilation, RH, Relative humidity, VE, Minute ventilation

 

 (Supported by an educational grant from Merck & Co., Inc.)

 Series editors: Joshua A. Boyce, MD, Fred Finkelman, MD, William T. Shearer, MD, PhD, and Donata Vercelli, MD

 Research by K.W.R. is supported by the American Heart Association and the World Anti-Doping Agency. Clinical trials performed in the Human Physiology Laboratory are supported by Forest Laboratories, Merck Inc, Pharmaxis, Schering-Plough, and SkyePharma.

 Terms in boldface and italics are defined in the glossary on page 239.

PII: S0091-6749(08)01137-8

doi:10.1016/j.jaci.2008.06.014

The Journal of Allergy and Clinical Immunology
Volume 122, Issue 2 , Pages 238-246, August 2008